LQDA — Liquidia Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819576 ·
Last close
$28.02
Market Cap
$2.51B
52W High
$93.61
52W Low
$21.94
ADV30
3,522,732
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 171,679,000 | 160,129,000 | 85,517,000 | 74,722,000 | 521,918,000 | 284,181,000 | 326,804,000 |
| Mar 2026 | 132,865,000 | 121,013,000 | 61,504,000 | 52,862,000 | 401,533,000 | 222,786,000 | 292,954,000 |
| Dec 2025 | 92,021,000 | 84,966,000 | 19,787,000 | 14,555,000 | 327,934,000 | 190,680,000 | 283,186,000 |
| Sep 2025 | 54,342,000 | 51,169,000 | 1,767,000 | -3,533,000 | 275,981,000 | 157,496,000 | 253,929,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$47,983,000
Investing CF
$-8,836,000
Financing CF
$17,385,000
CapEx
$-8,836,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.14
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-573,451,000
Inventory
$28,506,000
Receivables
$74,157,000
ST Investments
—
EBIT TTM
$52,221,000
Pretax Income TTM
$26,225,000
Interest Exp TTM
$25,996,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$450,907,008
EBITDA
$169,768,000
Free Cash Flow
$74,296,128
Enterprise Value
$5,872,538,624
Total Cash
$284,180,992
Total Debt
$182,896,000
Shares Out
89,508,891
Trailing EPS
$1.40
Book Value
$2.19
ROE
131.8%
ROA
27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 158,320,000 | -51,376,000 | -68,924,000 | 327,934,000 | 283,186,000 | 44,748,000 | -35,686,000 |
| Dec 2024 | 13,996,000 | -121,294,000 | -128,291,000 | 230,313,000 | 150,935,000 | 79,378,000 | -93,422,000 |
| Dec 2023 | 17,488,000 | -73,384,000 | -78,502,000 | 118,332,000 | 71,039,000 | 47,293,000 | -41,564,000 |
| Dec 2022 | 15,935,000 | -38,770,000 | -41,015,000 | 129,198,000 | 38,776,000 | 90,422,000 | -28,588,000 |
TTM Snapshot
Revenues TTM
$288,065,000
NetIncome TTM
$22,305,000
OpCashFlow TTM
—
Assets (Latest)
$401,533,000
Forward EPS
$5.65
Max Pain — expiry 2026-10-16
max pain strike: $35.00 · spot: $27.38 · call oi: 12,440 · put oi: 26,571
Expected Move to 2026-10-16:
±$4.45
(16.25%) —
implied range
$22.93 –
$31.83
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | $2.49B | $21.26 | — |
| MBX | MBX Biosciences, Inc. | $2.56B | $53.25 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.45B | $42.14 | — |
| HCM | HUTCHMED (China) Ltd | $2.38B | $13.67 | — |
| IRON | Disc Medicine, Inc. | $2.33B | $60.77 | — |
News headlines (Yahoo Finance, 1h cache)
Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access
2026-10-07 08:10 · Yahoo
Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades
2026-10-02 10:40 · Yahoo
United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
2026-10-01 20:56 · Yahoo
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
2026-10-01 20:45 · Yahoo
LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path
2026-10-01 18:07 · Yahoo
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
2026-10-01 16:30 · Yahoo
United Therapeutics Won Its Patent War and Liquidia Collapsed
2026-10-01 15:07 · Yahoo
Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss
2026-10-01 14:14 · Yahoo
Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling. An Appeal Could Decide Whether Shares Rebound.
2026-10-01 05:03 · Yahoo
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent
2026-10-01 01:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.